Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

BioMed Central full text link BioMed Central Free PMC article
Full text links

Actions

Share

Meta-Analysis
.2018 Nov 12;16(1):205.
doi: 10.1186/s12916-018-1193-5.

Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

Affiliations
Meta-Analysis

Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

Shan-Yan Gao et al. BMC Med..

Abstract

Background: In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malformations in infants has been the subject of much discussion and controversy. The aim of this study is to systematically review the associations between SSRIs use during early pregnancy and the risk of congenital malformations, with particular attention to the potential confounding by indication.

Methods: The study protocol was registered with PROSPERO (CRD42018088358). Cohort studies on congenital malformations in infants born to mothers with first-trimester exposure to SSRIs were identified via PubMed, Embase, Web of Science, and the Cochrane Library databases through 17 January 2018. Random-effects models were used to calculate summary relative risks (RRs).

Results: Twenty-nine cohort studies including 9,085,954 births were identified. Overall, use of SSRIs was associated with an increased risk of overall major congenital anomalies (MCAs, RR 1.11, 95% CI 1.03 to 1.19) and congenital heart defects (CHD, RR 1.24, 95% CI 1.11 to 1.37). No significantly increased risk was observed when restricted to women with a psychiatric diagnosis (MCAs, RR 1.04, 95% CI 0.95 to 1.13; CHD, RR 1.06, 95% CI 0.90 to 1.26). Similar significant associations were observed using maternal citalopram exposure (MCAs, RR 1.20, 95% CI 1.09 to 1.31; CHD, RR 1.24, 95% CI 1.02 to 1.51), fluoxetine (MCAs, RR 1.17, 95% CI 1.07 to 1.28; CHD, 1.30, 95% CI 1.12 to 1.53), and paroxetine (MCAs, RR 1.18, 95% CI 1.05 to 1.32; CHD, RR 1.17, 95% CI 0.97 to 1.41) and analyses restricted to using women with a psychiatric diagnosis were not statistically significant. Sertraline was associated with septal defects (RR 2.69, 95% CI 1.76 to 4.10), atrial septal defects (RR 2.07, 95% CI 1.26 to 3.39), and respiratory system defects (RR 2.65, 95% CI 1.32 to 5.32).

Conclusions: The evidence suggests a generally small risk of congenital malformations and argues against a substantial teratogenic effect of SSRIs. Caution is advisable in making decisions about whether to continue or stop treatment with SSRIs during pregnancy.

Keywords: Antidepressant; Cohort studies; Congenital malformations; Meta-analysis; Pregnancy; Serotonin uptake inhibitors.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
PRISMA of evidence search and selection for SSRIs use in early pregnancy and congenital malformations
Fig. 2
Fig. 2
Risk of congenital malformations in infants, according to maternal exposure to SSRIs. Relative risks and 95% confidence intervals are presented to show the risk of congenital malformations among infants born to women with exposure to SSRIs during the first trimester, as compared with the risk among infants born to women in the general population without such exposure. SSRIs, selective serotonin reuptake inhibitors
Fig. 3
Fig. 3
Risk of major congenital anomalies in infants, according to maternal exposure to SSRIs. Relative risks and 95% confidence intervals are presented to show the risk of major congenital anomalies among infants born to women with exposure to SSRIs during the first trimester, as compared with the risk among infants born to women without such exposure. SSRIs, selective serotonin reuptake inhibitors
Fig. 4
Fig. 4
Risk of congenital heart defects in infants, according to maternal exposure to SSRIs. Relative risks and 95% confidence intervals are presented to show the risk of congenital heart defects among infants born to women with exposure to SSRIs during the first trimester, as compared with the risk among infants born to women without such exposure. SSRIs, selective serotonin reuptake inhibitors
Fig. 5
Fig. 5
Risk of septal defects in infants, according to maternal exposure to SSRIs. Relative risks and 95% confidence intervals are presented to show the risk of septal defects among infants born to women with exposure to SSRIs during the first trimester, as compared with the risk among infants born to women in the general population without such exposure. SSRIs, selective serotonin reuptake inhibitors
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ornoy A, Koren G. Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy. Semin Fetal Neonatal Med. 2014;19(3):188–194. doi: 10.1016/j.siny.2013.11.007. - DOI - PubMed
    1. Berard A, Zhao J, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7:e0133721. doi: 10.1136/bmjopen-2016-013372. - DOI - PMC - PubMed
    1. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One. 2013;8(4):e63034. doi: 10.1371/journal.pone.0063034. - DOI - PMC - PubMed
    1. Taouk LH, Matteson KA, Stark LM, Schulkin J. Prenatal depression screening and antidepressant prescription: obstetrician-gynecologists’ practices, opinions, and interpretation of evidence. Arch Womens Ment Health. 2018;21(1):85–91. doi: 10.1007/s00737-017-0760-7. - DOI - PubMed
    1. Liu Y, Zhou X, Zhu D, Chen J, Qin B, Zhang Y, et al. Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis. Hum Psychopharmacol. 2015;30(3):132–142. doi: 10.1002/hup.2465. - DOI - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
BioMed Central full text link BioMed Central Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp